CGRP Inhibition, Autonomic Function, and Migraine
Eligible age
18–64 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) class of drugs affects the autonomic functions. The aim is not to investigate the effect of CGRP-mAb on migraine frequency. Calcitonin gene-related peptide (CGRP) is a neurotransmitter in the nervous system that plays an essential role in the development of migraine headache. Monoclonal antibodies can block the function of this messenger substance. Several studies have shown that this blockade leads to a reduction in the frequency of migraine. In addition to its role in migraine, CGRP also acts on the blood vessels and the autonomic nervous system. The autonomic nervous system is responsible for everything we have no control over in our body. This includes everything from heart rate and blood pressure to our digestion.
Sponsor: Medical University of Vienna
You may qualify if…
- ✓ Chronic migraine according to ICHD-3
- ✓ Episodic migraine without aura or with aura according to ICHD-3
- ✓ Unsuccessful treatment with 3 or more established prophylactic drugs
- ✓ Medicine costs are covered by health insurance
- ✓ Healthy controls must be free from any diagnosed chronic disease or acute infection requiring medication
You may not qualify if…
- ✕ Pregnancy and lactation
- ✕ Neurosurgical interventions performed within the last 12 months
- ✕ Coronary bypass surgery or revascularization procedures performed within the last 12 months
- ✕ History of transient ischemic attacks (TIA), stroke, stable or unstable angina pectoris, myocardial infarction or uncontrolled hypertension
- ✕ Known hypersensitivity to therapy with an anti-CGRP Antibodies
- ✕ History of a disorder (other than migraine) that may affect the results of autonomic tests
- ✕ Healthy controls must have no personal or family history of migraine
Source: ClinicalTrials.gov · NCT04628429 · last updated 2024-12-10